This includes enoxaparin sodium, designed for this condition, and recently included in the National Health System.

It is one of 20 high-impact scientific and technological results of this mega-company, which produces medicines, equipment, and high-tech services aimed at improving human health, generating exportable goods, and producing food using cutting-edge technology.

In addition to this, the company has registered and industrialized the vitamin B complex, Polivitsina, and Lisinopril tablets with Hydrochlorothiazide in 20 and 25 milligram strengths, as well as evaluating the effects of long-term treatment with policosanol (PPG) plus aspirin on the functional recovery of patients with ischemic stroke and subsequent cognitive impairment.

The company, founded in 2012 and comprised of 47 companies, 164 production lines, and 21 Science and Technology units, reports the development of an animal biomodel for the study of metabolic syndrome in humans as one of its achievements in the past year.

It also secured two registrations: the sanitary registration for Sincronida, for use in bovine reproduction, and the definitive registration of the monoclonal antibody Racotumamab, as maintenance therapy for patients with advanced non-small cell lung cancer.

In statements to the Granma newspaper, BioCubaFarma Vice President Santiago Dueñas specified that clinical trials have reported evidence of the favorable effect of the drug Jusvinza in the treatment of patients with sequelae of Chikungunya.

The first clinical trial of the same drug has also begun in China, for its future use in the therapeutic regimen for rheumatoid arthritis.

abo/arm/mem/alb